Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
|Videos|March 2, 2019
Dr. Casulo on Predicting Outcomes in Follicular Lymphoma
Author(s)Carla Casulo, MD
Carla Casulo, MD, discusses several different factors that can help predict outcomes in patients with follicular lymphoma.
Advertisement
Carla Casulo, MD, associate professor, Department of Medicine, University of Rochester Medical Center, discusses several different factors that can help predict outcomes in patients with follicular lymphoma.
At the time of diagnosis, the Follicular Lymphoma International Prognostic Index (FLIPI) and FLIPI2 scores can assist physicians in predicting response to therapy. In addition, epigenetic markers can be combined with clinical factors to predict whether patients will have worse or better outcomes; this is called the M7FLIPI.
Advertisement
Related to this article
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Higher EO2463-induced CD8 T-cell expansion was associated with significantly longer PFS in indolent non-Hodgkin lymphoma.
The IL-10–expressing anti-CD19 CAR T-cell therapy produced a 92.9% complete response rate and a 92.9% 1-year overall survival rate in high-risk relapsed/refractory DLBCL.
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
3
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
4
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
5